Evidence map›Paper›PMID 26864050›Full record

ArticleHuman vaccines & immunotherapeutics2016

DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.

Anne Flörcken, Joachim Kopp, Uwe Kölsch, Christian Meisel, Bernd Dörken, Antonio Pezzutto, Jörg Westermann

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anne Flörckena Department of Hematology , Oncology, and Tumor Immunology, Charité- University Medicine, Campus-Virchow-Klinikum , Berlin , Germany.
Joachim Koppc Experimental and Clinical Research Center (ECRC), Charité- University Medicine, Campus Berlin-Buch , Berlin , Germany.
Uwe Kölschb Labor Berlin Charité Vivantes GmbH , Berlin , Germany.
Christian Meiselb Labor Berlin Charité Vivantes GmbH , Berlin , Germany.
Bernd Dörkena Department of Hematology , Oncology, and Tumor Immunology, Charité- University Medicine, Campus-Virchow-Klinikum , Berlin , Germany.
Antonio Pezzuttoe Department of Hematology , Oncology, and Tumor Immunology, Charité- University Medicine Berlin, Campus Benjamin Franklin , Berlin , Germany.
Jörg Westermanna Department of Hematology , Oncology, and Tumor Immunology, Charité- University Medicine, Campus-Virchow-Klinikum , Berlin , Germany.
Charité - Universitätsmedizin Berlin · DEVivantes Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Chronic Myeloid Leukemia (CML), standard treatment consists of modern tyrosine-kinase inhibitors (TKI). Nevertheless, there is evidence that immune responses against leukemia-associated antigens (LAA) may play an important role in disease control. Dendritic cell (DC)- based immunotherapy is able to induce T cell responses against LAA and might therefore pose an interesting therapeutic option in CML, especially in the setting of minimal residual disease (MRD). GMP production of DC for clinical vaccination remains a time- and cost- intensive procedure and standardized DC generation is warranted. We asked whether maturation-induction with IFN-γ and IFN-α has an influence on functional properties of DC derived from peripheral blood mononuclear cells (PBMC) in CML patients. Monocyte-derived DC from healthy donors and from patients with CML were analyzed after maturation-induction with our TNF-α-containing standard cytokine cocktail with or without addition of IFN-α and/or IFN-γ. Our results confirm that the addition of IFN-γ leads to enhanced IL-12 secretion in healthy donors. In contrast, in CML patients, IFN-γ was not able to increase IL-12 secretion, possibly due to a higher degree of cell adherence and lower cell yield during the cell culture. Our data suggest, that- in contrast to healthy donors-, additional interferons are not beneficial for maturation induction during large-scale DC production in patients with CML.

Indexed as

Cell DifferentiationCells, CulturedDendritic CellsHumansImmunotherapyInterferon-alphaInterferon-gammaInterleukin-12Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukocytes, MononuclearNeoplasm, ResidualTumor Necrosis Factor-alphaInterferon-alphaInterferon-gammaInterleukin-12Tumor Necrosis Factor-alphaCMLDC activationDC generationdendritic cellsmonocyte-derived DC

Identifiers

PMID26864050
PMCPMC4963053
OpenAlexW2344234129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.